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Letter to the Editor
An Epitope of Bacillus anthracis Protective Antigen That Is Cryptic in
Rabbits May Be Immunodominant in Humans
In a recent article, Oscherwitz et al. endeavor to enhance the
immunogenicity of a multiple antigenic peptide (MAP) vaccine
that targets a loop-neutralizing determinant (LND) of Bacillus
anthracis protective antigen (PA) (1). They showed in a previous
study (2) that this MAP, consisting of four copies of amino acids
305 to 319 of PA (PA 305-319) extending from a lysine core, can
elicit humoral immunity in rabbits that is specific and strongly
neutralizing for the 22-23 loop in domain 2 of PA. However,
LND-specific antibodies were not detected in rabbits immunized
with whole PA, and it was concluded that PA 305-319 may be a
cryptic epitope. T cell assays in PA 305-319-immunized mice
showed that this peptide appeared to lack activity as a T helper
cell epitope.
We have good evidence that humans exposed to PA, either
following cutaneous anthrax infection or through vaccination,
generate long-term, T cell memory to both whole PA and PA
305-319. In a study including samples from naturally exposed
patients recovered from cutaneous anthrax, from vaccine-hyper-
immunized AVP (anthrax vaccine precipitated) donors, and from
recombinant PA-vaccinated donors, positive T cell gamma inter-
feron (IFN-) enzyme-linked immunospot (ELISPOT) assay re-
sponses were detected across all groups on restimulation of pe-
ripheral blood mononuclear cells (PBMC) with both whole PA
and PA 305-319 (Table 1; unpublished data). This shows that
humans exposed to B. anthracis and whole PA recognize and
generate memory to PA 305-319, suggesting that it is immuno-
dominant rather than cryptic. Donors expressed a range of HLA
haplotypes, with a majority being HLA-DR4 positive. While
many important discoveries on the immunology of infection are
made in experimental models, the human T cell response to PA
in this respect differs from that of both rabbits and mice.
In this light, the epitope used by Oscherwitz and colleagues
may indeed be more relevant to eliciting appropriate human
immunity than previously envisaged.
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Authors’ Reply
Ingram and colleagues present interesting evidence that the
305-319 peptide from PA is recognized by human T cells from
PA vaccinees and anthrax survivors as evidenced by ELISPOT
assays. We are not surprised that this segment would be seen
by T cells in some human subjects and believe that more
extensive examination of the human T cell response to PA in
general and with regard to the LND specifically would be of
significant interest.
We utilized inbred mice to model the likely performance of
our LND immunogens in outbred rabbits. Our data demon-
strated that the LND peptide was devoid of helper T cell
activity in multiple strains of inbred mice. This determination
led us to evaluate the immunogenicity in rabbits of the LND
peptide linked to a heterologous source of helper T cell stim-
ulation, since it has long been established that T cell-depen-
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dent antibody responses to haptenic peptide sequences require
a covalently linked source of helper T cell stimulation (6).
Indeed, our data for rabbits demonstrated that the immuno-
genicity of the LND peptide linked to a helper T cell epitope
from tetanus toxoid was significantly higher than the immuno-
genicity of the peptide without a linked source of T cell help (4,
5). It is important to note, however, that our studies did not
examine whether the 305-319 sequence is capable of stimulat-
ing T cells in rabbits or in humans. While the ELISPOT data
indicate that the 304-319 sequence can be recognized by hu-
man T cells, we would be reluctant to conclude that the 304-
319 sequence is immunodominant in humans without clear
demonstration that the recognition of this peptide by T cells is
comparatively superior to the recognition of most other pep-
tide sequences processed from within PA. If future studies
were to confirm that the 305-319 sequence is immunodominant
in humans, this could have implications for the use of this
peptide in anthrax vaccines, especially in regard to the induc-
tion of anamnestic immunity among LND vaccinees exposed
to PA.
We believe it would be helpful to clarify the usage of the
term “cryptic” in our papers. Our data show that the LND
peptide sequence appears to be immunologically silent or cryp-
tic in PA as a target for humoral immunity in rabbits; immu-
nization of rabbits with PA does not stimulate antibody to the
LND. Evidence also exists that the LND may be cryptic at the
level of the B cell in humans immunized with PA. Cryptic B
cell epitopes have been reported in many proteins, including in
the circumsporozoite protein of Plasmodium falciparum (7), in
HIV gp120 (1), and in the hemagglutinin protein of influenza
virus (2, 8), among others. The explanation for the crypticity of
the LND is not currently known, but may be related to complex
protein structural features associated with the 22-23 loop in
domain 2 of PA where this sequence is found (3).
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TABLE 1. T cell IFN- responses to PA 305-319 in PBMC of
vaccinated and naturally exposed subjects
Donora HLA-DR type Response to PA305-319b
CA1 4, 14 
CA2 4, 14 
AVP1 11, 13 
AVP2 7, 15 
rPA1 4, 17 
rPA2 4, 9 
rPA3 4, 15 
a CA, naturally exposed patient recovered from cutaneous anthrax; AVP, AVP
vaccine-hyperimmunized donor; rPA, recombinant-PA-vaccinated donor.
b Evaluated by IFN- ELISPOT of peptide PA 305-319-restimulated PBMC
cultures. , positive T cell response defined as spot-forming cell number greater
than 2 standard deviations from the no-peptide control triplicates.
2354 LETTER TO THE EDITOR INFECT. IMMUN.
 o
n
 February 24, 2014 by Cardiff Univ
http://iai.asm
.org/
D
ow
nloaded from
 
